Mednet Logo
HomeCardiologyQuestion

Following completion of antiplatelet monotherapy (i.e., Plavix) plus oral anticoagulation in patients with AFib post-PCI, would you favor continuing antiplatelet therapy + OAC, switching from Plavix to aspirin and continuing OAC, or stopping antiplatelet therapy and continuing OAC?

3
3 Answers
Mednet Member
Mednet Member
Cardiology · Corewell Health Medical Center

My practice has always been to continue ASA in addition to anticoagulation but I'm starting to change this practice and remove antiplatelet therapy and continue OAC alone, especially in higher bleeding risk patients. There have been a couple of studies (AFIRE and OAC-ALONE) that would seem to suppor...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Cardiology · Langhorne Cardiology Consultants Inc

The current ACC guidelines recommend stopping anti-platelet agent after one year and continuing DOACs.

Register or Sign In to see full answer

Mednet Member
Mednet Member
Cardiology · Geisinger Medical Center

To avoid confusion with different styles within our system, we have adopted a standard practice in our lab to use triple therapy for 1 week. Then after 1 week, we drop ASA. We tend to prefer ASA, clopidogrel + OAC. But if they could not take clopidogrel (for any reason) then we still use the same pr...

Register or Sign In to see full answer

Following completion of antiplatelet monotherapy (i.e., Plavix) plus oral anticoagulation in patients with AFib post-PCI, would you favor continuing antiplatelet therapy + OAC, switching from Plavix to aspirin and continuing OAC, or stopping antiplatelet therapy and continuing OAC? | Mednet